S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NYSE:CRL

Charles River Laboratories International Stock Forecast, Price & News

$273.72
+6.81 (+2.55 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$265.01
Now: $273.72
$274.03
50-Day Range
$226.35
MA: $247.67
$276.31
52-Week Range
$95.58
Now: $273.72
$278.08
Volume328,245 shs
Average Volume331,951 shs
Market Capitalization$13.62 billion
P/E Ratio45.62
Dividend YieldN/A
Beta1.12
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.
Charles River Laboratories International logo

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

288th out of 1,480 stocks

Commercial Physical Research Industry

8th out of 33 stocks

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP15986410
Phone781-222-6000
Employees17,100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.62 billion
Cash Flow$10.98 per share
Book Value$33.45 per share

Profitability

Net Income$252.02 million

Miscellaneous

Market Cap$13.62 billion
Next Earnings Date2/9/2021 (Estimated)
OptionableOptionable
$273.72
+6.81 (+2.55 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Charles River Laboratories International (NYSE:CRL) Frequently Asked Questions

How has Charles River Laboratories International's stock price been impacted by Coronavirus (COVID-19)?

Charles River Laboratories International's stock was trading at $136.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRL stock has increased by 100.4% and is now trading at $273.72.
View which stocks have been most impacted by COVID-19
.

Is Charles River Laboratories International a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 4 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Charles River Laboratories International stock.
View analyst ratings for Charles River Laboratories International
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Charles River Laboratories International?

Wall Street analysts have given Charles River Laboratories International a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Charles River Laboratories International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Charles River Laboratories International's next earnings date?

Charles River Laboratories International is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for Charles River Laboratories International
.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) released its earnings results on Thursday, October, 29th. The medical research company reported $2.33 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.80 by $0.53. The medical research company had revenue of $743.30 million for the quarter, compared to analysts' expectations of $715.63 million. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%. The company's revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.69 EPS.
View Charles River Laboratories International's earnings history
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International issued an update on its FY20 earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of $7.75-7.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.26. The company issued revenue guidance of +9.5-10.5% yr/yr to $2.87-2.90 billion, compared to the consensus revenue estimate of $2.85 billion.

What price target have analysts set for CRL?

18 brokers have issued 1-year target prices for Charles River Laboratories International's stock. Their forecasts range from $145.00 to $265.00. On average, they expect Charles River Laboratories International's share price to reach $214.67 in the next year. This suggests that the stock has a possible downside of 21.6%.
View analysts' price targets for Charles River Laboratories International
or view Wall Street analyst' top-rated stocks.

Who are some of Charles River Laboratories International's key competitors?

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), The Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), salesforce.com (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Who are Charles River Laboratories International's key executives?

Charles River Laboratories International's management team includes the following people:
  • Mr. James C. Foster, Chairman, CEO & Pres (Age 69, Pay $5.38M)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 54, Pay $1.25M)
  • Mr. Joseph W. LaPlume, Corp. Exec. VP of Corp. Devel. & Strategy (Age 46, Pay $931.56k)
  • Ms. Birgit Girshick, Corp. EVP of Global Discovery & Safety Assessment, Biologics Testing Solutions & Avian Vaccine (Age 50, Pay $937.58k)
  • Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 43)
  • Mr. Arthur C. Hubbs, Corp. Sr. VP & Chief Information Officer
  • Todd Spencer, Corp. VP of Investor Relations
  • Mr. Matthew L. Daniel, Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
  • Ms. Amy Cianciaruso, Corp. VP of PR & Corp. Communications
  • Ms. Gina M. Mullane, Chief Marketing Officer & Corp. Sr. VP

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Investment House LLC (0.19%), Boston Trust Walden Corp (0.13%), Crossmark Global Holdings Inc. (0.04%), State of Alaska Department of Revenue (0.02%), Signature Estate & Investment Advisors LLC (0.01%) and First Hawaiian Bank (0.01%). Company insiders that own Charles River Laboratories International stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo.
View institutional ownership trends for Charles River Laboratories International
.

Which major investors are selling Charles River Laboratories International stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including A. D. Beadell Investment Counsel Inc., First Hawaiian Bank, Sowell Financial Services LLC, CFO4Life Group LLC, Signature Estate & Investment Advisors LLC, and MADDEN SECURITIES Corp. Company insiders that have sold Charles River Laboratories International company stock in the last year include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Robert J Bertolini, Stephen D Chubb, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories International
or view top insider-selling stocks.

Which major investors are buying Charles River Laboratories International stock?

CRL stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Boston Trust Walden Corp, Fulton Bank N.A., Diversified Trust Co, Rowland Carmichael Advisors Inc. ADV, Crossmark Global Holdings Inc., Raymond James Trust N.A., and Investment House LLC.
View insider buying and selling activity for Charles River Laboratories International
or or view top insider-buying stocks.

How do I buy shares of Charles River Laboratories International?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $273.72.

How big of a company is Charles River Laboratories International?

Charles River Laboratories International has a market capitalization of $13.62 billion and generates $2.62 billion in revenue each year. The medical research company earns $252.02 million in net income (profit) each year or $6.73 on an earnings per share basis. Charles River Laboratories International employs 17,100 workers across the globe.

What is Charles River Laboratories International's official website?

The official website for Charles River Laboratories International is www.criver.com.

How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.